摘要
目的探讨糖维胶囊治疗2型糖尿病(T2DM)患者的疗效及安全性。方法选择2013年2月至2016年4月我院收治的200例T2DM患者,按随机数字表法分为对照组与观察组各100例,对照组采用糖尿病常规治疗,观察组加用糖维胶囊治疗,均治疗12周,比较两组治疗前后空腹血糖(FPG)、餐后2h血糖(2h PBG)、糖化血红蛋白(Hb A1c)、C肽(CP)、胰岛素水平(FINS)、餐后2h胰岛素(2h INS)、胰岛素敏感指数(HOMA-IS)、胰岛β细胞功能指数(HOMA-β)等血糖及胰岛素功能指标的改善情况,比较两组治疗效果,监测两组治疗不良反应发生率。结果 (1)治疗前,两组FPG、2h PBG、Hb A1c、CP、FINS、2h INS、HOMA-IS、HOMA-β比较差异无统计学意义(P>0.05),治疗后,两组FPG、2h PBG、Hb A1c均降低,CP、FINS、2h INS、HOMA-IS、HOMA-β均上升,与同组治疗前比较差异有统计学意义(P<0.05),观察组FPG、2h PBG、Hb A1c下降幅度及CP、FINS、2h INS、HOMA-IS、HOMA-β上升幅度均高于对照组(P<0.05);(2)观察组治疗总有效率高于对照组(P<0.05),但两组不良反应发生率比较差异无统计学意义(P>0.05)。结论糖维胶囊可降低T2DM患者血糖水平,提高患者胰岛β细胞功能,优化T2DM治疗效果,且安全性肯定。
Objective To investigate the efficacy and safety of Tangwei capsules in the treatment of type 2 diabetes mellitus（T2DM）. Methods 200 cases of patients with T2DM treated in our hospital from February 2013 to April 2016 were selected and randomly divided into the control group and the observation group by random number table method, with 100 cases in each group. Both groups were given conventional treatment for diabetes and the observation group were additionally treated with Tangwei capsule. All patients were treated for 12 weeks. The improvement of blood glucose and islet function indexes such as fasting plasma glucose（ FPG ）, postprandial 2h plasma glucose （2hPBG）, glycosylated hemoglobin （ HbAlc ）, C peptide （ CP）, fasting insulin （ FINS ）, postprandial 2h insulin （ 2hlNS ）, insulin sensitivity index （ HOMA-IS ） and islet β cell function index （ HOMA-β） was compared between the two groups. The therapeutic effects were compared between the two groups and the incidence of adverse reactions in the two groups was monitored. Results ①Before treatment, there was no significant difference between the two groups in FPG, 2hPBG, HbA1 c, CP, FINS, 2hlNS, HOMA- IS or HOMA-β（ P 〉 0.05 ）. After treatment, FPG, 2hPBG and HbA1 c decreased while CP, FINS, 2hlNS, HOMA-IS and HOMA-β increased in the two groups. Compared within the same group before treatment, there were significant differences （ P 〈 0.05 ）. The changes of above indexes were more obvious in the observation group than the control group （ P 〈 0.05 ）. ②The total effective rate of treatment in the observation group was higher than that in the control group （ P 〈 0.05 ）, but there was no significant difference in the incidence of adverse reactions between the two groups （ P 〉 0.05 ）. Conclusion Tangwei capsule can reduce the blood glucose level in patients with T2DM, improve the function of pancreatic β cell and optimize the curative effect of T2DM, with safety.
出处
《标记免疫分析与临床》
CAS
2018年第1期83-86,共4页
Labeled Immunoassays and Clinical Medicine
关键词
2型糖尿病
糖维胶囊
血糖
胰岛功能
Type 2 diabetes mellitus
Tangwei capsule
Blood glucose
Islet function
